The corneal endothelium – a thin layer of cells on the cornea of the eye – is essential for maintaining corneal transparency and, therefore, vision. Any severe impairment of the corneal endothelium causes a loss of transparency due to a process termed endothelial decompensation that leads to vision loss. One leading cause of vison loss due to corneal endothelial decompensation is Fuchs endothelial corneal dystrophy (FECD), which has a prevalence of 4% in the Caucasian population over 40 years of age. The usual treatment for FECD is corneal transplantation, but this procedure has associated problems, especially a shortage of donor corneas. Other issues include graft failure (at both early and late phases) and the difficulty of the surgical transplantation procedure. Therefore, novel therapies that replace corneal transplantation with cell-therapy and pharmaceutical treatments are welcomed.
ActualEyes Inc. has as its business objectives the development and commercialization of two specific products: 1) eye drops for the treatment of FECD and 2) a cell-therapy product for treatment of corneal endothelial decompensation.